Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
About this episode
Dr Aaron Lisberg discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.
Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here .
People in this episode
Host: Dr. Neil Love
Guest: Dr Aaron Lisberg
Topics covered
- lung cancer
- antibody-drug conjugates
- TROP2
- non-small cell lung cancer
- medical research
Keywords
- lung cancer
- TROP2
- antibody-drug conjugates
- non-small cell lung cancer
- CME information
Mentioned in this episode
Organizations: University of California, Los Angeles
Products: TROP2-directed antibody-drug conjugates
Places: non-small cell lung cancer
More episodes of Lung Cancer Update
- EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
- Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
- Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy
- Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
- Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
- HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
Explore listener stats, chart rankings, contacts and more on the Lung Cancer Update podcast page.